BriaCell Therapeutics has priced a best-efforts public offering of 5,366,726 units, generating gross proceeds of approximately $30 million before fees and expenses. Each unit comprises one common share (or a pre-funded warrant in lieu) and one warrant; the warrants have been approved for listing on the Nasdaq Capital Market under the symbol “BCTXL” and are expected to begin trading on January 14, 2026. Each warrant is immediately exercisable for one common share at an exercise price of $6.93 and will expire five years from issuance. The offering is scheduled to close on January 15, 2026, subject to customary conditions, and ThinkEquity is acting as sole placement agent.

In the Phase 1/2a study of Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy, a 78-year-old hormone receptor-positive, HER2-negative metastatic breast cancer patient achieved and sustained 100% resolution of a lung metastasis for 11 months following four doses. This patient, the first enrolled in the trial, received 17 cycles of monotherapy, reported no treatment-limiting toxicities and maintained stable disease at all other evaluable sites. With dose escalation complete, the trial has now entered a Phase 2a expansion combining Bria-OTS with an immune checkpoint inhibitor, positioning BriaCell to validate combination strategies in a resistant patient population.